Shionogi Books 110 Billion Yen Sales for Yet-to-Be-Approved COVID Pill, Vaccine: FY2022 Outlook

To read the full story

• Sign In
• Subscribe

Related Article

• Shionogi Sees Flat 1H Results, Gains Domestic Support from Torii
  October 28, 2025

• Shionogi Nets Record Earnings for 3rd Consecutive Year on Overseas Expansion
  May 13, 2025

• Shionogi’s H1 Sales Dip on One-Off Factor, HIV Franchise Grows
  October 29, 2024

• Shionogi Renews Record Earnings in FY2023, Driven by Xocova and Xofluza
  May 14, 2024

• Shionogi Notches Record Earnings in April-September, Xocova Drives Growth
  November 1, 2023

• Shionogi Logs Record Earnings Q1 on Xocova, ADHD License Transfer
  August 1, 2023

• Xocova’s Uptake in Japan in Line with Expectations: Shionogi CEO
  May 11, 2023

• Shionogi Hits Record High Earnings on Xocova Boon in FY2022
  May 11, 2023

• Shionogi Logs Record Profits as Xocova Nets 100 Billion Yen from Govt Purchase: April-December
  January 31, 2023

• Shionogi’s H1 Operating Profit Sinks 33.8% on COVID-Linked R&D Expenses
  November 1, 2022

• Shionogi’s Q1 Sales Up 4.2% on HIV Franchise, FX
  August 2, 2022

• Shionogi’s Sales Rise 12.8% in FY2021 on Cefiderocol Growth in US/Europe
  May 12, 2022

• Shionogi’s April-Dec. Operating Profit Tumbles 40%-Plus on Antibiotic Promotion, COVID R&D
  February 1, 2022

• Shionogi’s H1 Sales Wane 2.3% as Crestor Royalties Almost Disappear
  November 2, 2021

• Shionogi Sees Sales Dip in Q1 despite Japan Growth; Crestor Royalty Nearly Zero
  August 3, 2021

• Shionogi Incurs Double-Digit Sales Fall in FY2020 as Infectious Disease Meds Falter
  May 11, 2021

• Shionogi Sees Double-Digit Sales Decline in April-December as Infectious Disease Meds Suffer
  February 2, 2021

• Shionogi Sales Sag 9.3% in April-September on COVID-19, Price Cuts
  November 2, 2020

• Shionogi Suffers Double-Digit Dip on Q1 Earnings as COVID-19 Weighs
  August 3, 2020